Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-I: Long-Term Outcomes of Viekirax + Exviera in HCV GT1
NCT02219490Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Primary completion
- May 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 27
01
Overview
Phase 3, open-label, single-arm trial of paritaprevir and dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoints: All-Cause Death at 260 weeks, Liver-Related Death at 260 weeks and 3 more. Started Oct 2014; status: completed.
02
Drugs
paritaprevirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02219490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219490.